Anti-CTLA-4 and anti-PD-1/PD-L1 checkpoint inhibitors have shown promise in the treatment of melanoma, non-small-cell lung cancer, and bladder cancer. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.